KCM
CNCE

Kynam Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Kynam Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,420,349
Closed -$25.8M – 39
2022
Q4 		$25.8M Buy
4,420,349
+2,747,308
+164% +$14.4M 3.96% 9
2022
Q3 		$11.2M Buy
1,673,041
+673,041
+67% +$4.08M 2.36% 13
2022
Q2 		$4.21M Buy
+1,000,000
New +$3.96M 1.08% 19

Kynam Capital Management's CNCE Position: Q1 2023 in Review

Kynam Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 4,420,349 shares — an estimated $25.8M sold.

Kynam Capital Management first reported a position in CNCE in Q2 2022 and held it in 3 quarters. The position peaked at $25.8M in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

  • Kynam Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Kynam Capital Management sold 4,420,349 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $25.8M.
  • Kynam Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2022 and held it in 3 quarters.
  • Kynam Capital Management's Concert Pharmaceuticals, Inc. position peaked at $25.8M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Kynam Capital Management's 13F filing for Q1 2023, filed 15 May 2023.